Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Miconazole Lauriad to Treat Oropharyngeal Candidiasis in HIV Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with clinical picture of oropharyngeal candidiasis~* Confirmation of oropharyngeal candidiasis by candida culture positive~* HIV-positive patients~* Patients 18 years of age~Exclusion Criteria:~* Patients with signs or symptoms of systemic candidiasis~* Patients with signs or symptoms of esophagitis~* Pregnant or breast-feeding women~* Patients who have taken systemic antifungals within the past 30 days~* Patients who have taken local antifungals within the past 7 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clotrimazole (Type: ACTIVE_COMPARATOR): Clotrimazole troches, 10 mg, 5 times per day for 14 days
- miconazole Lauriad (Type: EXPERIMENTAL): Miconazole Lauriad 50 mg mucoadhesive buccal tablet, once daily, for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).